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Summary
Background Prostate cancer is a major public health problem with considerable uncertainties about the eﬀ ectiveness 
of population screening and treatment options. We report the study design, participant sociodemographic and clinical 
characteristics, and the initial results of the testing and diagnostic phase of the Prostate testing for cancer and 
Treatment (ProtecT) trial, which aims to investigate the eﬀ ectiveness of treatments for localised prostate cancer.
Methods In this randomised phase 3 trial, men aged 50–69 years registered at 337 primary care centres in nine UK 
cities were invited to attend a specialist nurse appointment for a serum prostate-speciﬁ c antigen (PSA) test. Prostate 
biopsies were oﬀ ered to men with a PSA concentration of 3·0 μg/L or higher. Consenting participants with clinically 
localised prostate cancer were randomly assigned to active monitoring (surveillance strategy), radical prostatectomy, 
or three-dimensional conformal external-beam radiotherapy by a computer-generated allocation system. 
Randomisation was stratiﬁ ed by site (minimised for diﬀ erences in participant age, PSA results, and Gleason score). 
The primary endpoint is prostate cancer mortality at a median 10-year follow-up, ascertained by an independent 
committee, which will be analysed by intention to treat in 2016. This trial is registered with ClinicalTrials.gov, number 
NCT02044172, and as an International Standard Randomised Controlled Trial, number ISRCTN20141297.
Findings Between Oct 1, 2001, and Jan 20, 2009, 228 966 men were invited to attend an appointment with a specialist 
nurse. Of the invited men, 100 444 (44%) attended their initial appointment and 82 429 (82%) of attenders had a PSA 
test. PSA concentration was below the biopsy threshold in 73 538 (89%) men. Of the 8566 men with a PSA 
concentration of 3·0–19·9 μg/L, 7414 (87%) underwent biopsies. 2896 men were diagnosed with prostate cancer (4% 
of tested men and 39% of those who had a biopsy), of whom 2417 (83%) had clinically localised disease (mostly T1c, 
Gleason score 6). With the addition of 247 pilot study participants recruited between 1999 and 2001, 2664 men were 
eligible for the treatment trial and 1643 (62%) agreed to be randomly assigned (545 to active monitoring, 545 to 
radiotherapy, and 553 to radical prostatectomy). Clinical and sociodemographic characteristics of randomly assigned 
participants were balanced across treatment groups.
Interpretation The ProtecT trial randomly assigned 1643 men with localised prostate cancer to active monitoring, 
radiotherapy, or surgery. Participant clinicopathological features are more consistent with contemporary patient 
characteristics than in previous prostate cancer treatment trials.
Funding UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © Lane et al. Open Access article distributed under the terms of CC BY.
Introduction
Prostate cancer is the most frequently diagnosed cancer 
in men in developed countries, with an estimated 
241 740 new cases and 28 171 deaths caused by the disease 
every year in the USA alone.1 In the UK, it is the second 
most common cause of cancer deaths in men (13%) with 
41 763 new cases diagnosed and 10 793 deaths caused by 
the disease in 2011.2 The disease can be detected early by 
prostate-speciﬁ c antigen (PSA) measurement followed 
by prostate biopsy. However, most screen-detected 
cancers are at low risk of progression, and potential harm 
could be caused by unnecessary diagnosis and treatment.
The publication of two population-based randomised 
controlled trials3,4 of screening has not resolved this 
dilemma. The European Randomized Study of Screening 
for Prostate Cancer (ERSPC)3 reported a clear but relatively 
small disease-speciﬁ c survival beneﬁ t from screening 
compared with no active intervention at 8 years’ and 
13 years’ follow-up, with a larger eﬀ ect reported in a smaller 
Scandinavian cohort at 14 years after diagnosis.4 By contrast, 
the US-based Prostate, Lung, Colorectal, and Ovarian 
(PLCO) trial5 reported no beneﬁ t from screening with a 
similar length of follow-up, but was limited by substantial 
contamination from previous PSA testing in the control 
group in more than 50% of the unscreened men.
Most men diagnosed with PSA-detected prostate cancer 
tend to undergo radical treatment. Active monitoring or 
surveillance with deferred radical treatment has been 
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advocated to avoid immediate, potentially unnecessary, 
intervention. However, absence of evidence about 
optimal protocols precludes a clear deﬁ nition of safety 
for this option. Two randomised trials6,7 have compared 
radical surgery with passive observation (so-called 
watchful waiting). The US-based Prostate cancer 
Intervention Versus Observation Trial (PIVOT)6 reported 
no overall mortality beneﬁ t from surgery in patients with 
PSA-detected cancer, whereas the Scandinavian Prostate 
Cancer Group 4 trial (SPCG-4)7 showed a clear disease-
speciﬁ c and overall survival beneﬁ t for surgery in patients 
presenting clinically, as well as a reduction in progression 
to metastatic disease.
The Prostate testing for cancer and Treatment (ProtecT) 
randomised trial was designed to assess the eﬀ ectiveness 
and cost-eﬀ ectiveness of active monitoring (a surveillance 
protocol), external beam conformal radiotherapy with 
neoadjuvant androgen suppression, and radical 
prostatectomy for men with PSA-detected clinically 
localised prostate cancer. Analysis of the primary 
outcome of disease-speciﬁ c mortality is scheduled for 
2016, at 10 years’ median follow-up. Here we present the 
trial design, the initial results of the PSA testing and 
diagnostic phase, and the clinical and sociodemographic 
characteristics of the randomly assigned participants.
Methods
Study design and participants
The ProtecT trial was designed in the late 1990s and early 
2000s to compare the major conventional treatments for 
patients with clinically localised prostate cancer detected 
through population-based PSA testing. The three 
treatments were radical prostatectomy, external beam 
three-dimensional (3D) conformal radiotherapy, and 
active monitoring.
Recruitment was undertaken in two stages: a feasibility 
pilot in three English cities (in 24 primary care centres 
linked to three university hospitals) from June, 1999, to 
September, 2001 (ISRCTN08435261), and the main trial 
from October, 2001, to January, 2009, in nine cities (seven 
in England, one in Scotland, and one in Wales).8
Also in 2001, the CAP trial (Cluster randomised triAl of 
PSA testing for Prostate cancer; ISRCTN92187251) 
commenced, which is an extension to the ProtecT trial. 
The CAP trial randomly assigned primary care centres to 
undertake either the ProtecT trial or standard UK 
National Health Service (NHS) management (no routine 
PSA testing; ﬁ gure 1), to assess population-based 
screening in addition to treatment eﬀ ectiveness of 
clinically localised disease identiﬁ ed in ProtecT.9 Further 
details of the CAP trial design and randomisation have 
been published previously.10
A written invitation was sent by 337 primary care 
centres assigned to undertake the ProtecT trial to 
registered men aged 50–69 years, excluding those with a 
previous malignancy (apart from skin cancer), renal 
transplant or on renal dialysis, major cardiovascular or 
respiratory comorbidities, bilateral hip replacement, or 
an estimated life expectancy of less 10 years. Men who 
responded received a ProtecT patient information sheet 
and an appointment with a specialist nurse who 
explained the complexities of PSA testing, assessed trial 
eligibility, and sought written informed consent. Previous 
PSA test results were checked in the medical records but 
were not an exclusion criterion. On postal receipt of a 
second written consent form, total PSA was analysed at 
site laboratories. Laboratories were audited by the NHS 
External Quality Assessment Service. Participants with a 
PSA concentration of at least 3·0 μg/L were invited to 
attend secondary care centres within the nine 
participating cities for a physical and digital rectal 
examination and standardised ten-core transrectal-
ultrasound-guided prostate biopsies. Participants with an 
initial PSA concentration at least 20·0 μg/L at diagnosis 
were excluded because of the high likelihood that they 
had more advanced cancer.
Patients were staged using a combination of digital 
rectal examination, PSA concentration, transrectal 
ultrasound-guided biopsies, and isotope bone scanning 
(if PSA was ≥10 μg/L). MRI was used for staging at the 
discretion of individual investigators, because this 
imaging technique was not available in all centres during 
the recruitment period. Men diagnosed with clinically 
localised prostate cancer and deemed ﬁ t for radical 
treatment received a ProtecT treatment patient 
information sheet, and were subsequently invited to 
discuss randomisation with the specialist nurses. Men 
with a PSA concentration of 10 μg/L or higher or a 
Gleason score of greater than 7 points underwent an 
isotope bone scan to exclude metastatic disease. Men 
initially diagnosed with benign biopsy samples, or locally 
advanced or advanced prostate cancer, were managed 
within the NHS and excluded from the trial. Men with a 
benign ﬁ rst biopsy sample and a free-to-total PSA ratio 
below 11%, or atypical small acinar proliferation or 
Figure 1: ProtecT and CAP trial recruitment phases and endpoint assessment
CAP=Cluster randomised triAl of PSA testing for Prostate cancer. ProtecT=Prostate 
testing for cancer and Treatment. NHS=National Health Service.
ProtecT pilot phase (1999–2001)
Intervention:
ProtecT main phase
CAP trial 
Randomisation and recruitment of primary care 
centres (2001–09)
ProtecT randomisation to three treatments
Usual care:
UK NHS policy
CAP and ProtecT endpoint committee:
Primary outcome is prostate cancer mortality at a median follow-up of 
10 years 
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For the study protocol see 
http://www.nets.nihr.ac.uk/
projects/hta/962099
high-grade prostatic intraepithelial neoplasia, were 
oﬀ ered further biopsies; if these repeat biopsy samples 
were benign, these men were managed in primary care 
and excluded from the trial. No further trial follow-up 
occurred after the one round of PSA testing or 
identiﬁ cation of cancers after referral to the NHS.
Approval was obtained from the UK Trent Multicentre 
Research Ethics Committee (01/4/025). Histopathologists 
at each site reported pathology ﬁ ndings on standardised 
forms and participated in trial quality control processes 
and those of the NHS Uropathology External Quality 
Assessment Scheme. The trial steering committee (seven 
independent members and chair) reviewed trial progress 
every year. Study training programmes and on-site 
monitoring visits were used to standardise trial conduct.11,12
Randomisation and masking
Men discussed treatment options with the specialist 
nurses, and if they agreed to the three-group randomisation 
(1:1:1), the nurse telephoned a central system in the Bristol 
trials’ oﬃ  ce (Bristol, UK) and logged participant details. 
Allocations were computer-generated as required for each 
participant, originally using Microsoft Excel functions, 
and subsequently in C++, stratiﬁ ed by site with stochastic 
minimisation to improve the balance across the groups in 
relation to age at primary care patient identiﬁ cation date, 
Gleason sum score (<7, 7, or 8–10 points) and mean of 
baseline and ﬁ rst biopsy PSA results (<6·0, 6·0–9·9, or 
>9·9 μg/L). The allocation was revealed after the entry of 
participant details, and then given to the participant by the 
nurse. Clinicians and participants were not masked to 
group assignment. Eligible participants were oﬀ ered the 
choice of a two-group randomisation (radical prostat-
ectomy or radiotherapy), or a three-group randomisation 
(with the addition of active monitoring to the two 
treatment groups). In 2003, the independent data 
monitoring committee (DMC) terminated the two-group 
option because of limited uptake, and the only option for 
participants who consented was the three-group 
randomisation throughout the remaining period of 
recruitment. Men who declined randomisation were 
oﬀ ered identical follow-up and formed a comprehensive 
cohort within the study design.
Procedures
Participant sociodemographic characteristics, family 
history of cancer, and previous PSA tests were obtained 
at recruitment. Clinical management after diagnosis was 
standardised in the trial protocol using study group-
speciﬁ c pathways. In all treatment groups, androgen 
deprivation therapy was oﬀ ered when serum PSA 
reached a concentration of 20 μg/L, or less if indicated. 
Imaging of the skeleton was recommended if serum 
PSA reached 10 μg/L, using isotope bone scintigraphy, 
plain radiographs, and MRI as necessary.
In patients randomly assigned to active monitoring, the 
protocol aim was to avoid immediate radical treatment 
while assessing the disease over time, with radical 
treatment oﬀ ered if disease progression was evident. PSA 
concentrations were measured and reviewed every 
3 months in the ﬁ rst year and twice yearly thereafter 
(frequency was changed as indicated). The specialist 
nurses also met with participants yearly to assess their 
overall health, and discuss graphical displays of PSA 
results and any concerns raised, overseen by each centre’s 
local clinical investigator. Changes in PSA concentrations 
were assessed at each visit, and a rise of at least 50% 
during the previous 12 months triggered repeat testing 
within 6–9 weeks. If the PSA concentrations were 
persistently raised, or the patient had any other concerns, 
a review appointment was made with the centre urologist 
for discussion of further tests including re-biopsy and all 
relevant management options.
In patients randomly assigned to receive external beam 
3D conformal radiotherapy, neoadjuvant androgen 
suppression was given for 3–6 months before and 
concomitantly with 3D-conformal radiotherapy delivered 
at 74 Gy in 37 fractions.13 Quality assurance followed the 
RT01 trial procedures.14,15 PSA concentrations were 
measured every 6 months for the ﬁ rst year and then 
yearly. The study oncologist held a review appointment 
with participants if the PSA concentrations rose by at 
least 2·0 μg/L post-nadir or concerns were raised about 
disease progression.16 Management options were 
discussed, including continued monitoring, further tests, 
salvage, radical, or palliative treatments as indicated.
In patients randomly assigned to receive radical 
prostatectomy, the predominant approach was open 
retropubic radical prostatectomy with individual-level 
quality assurance according to minimum standards.17 
Participants with a baseline PSA concen tration of at least 
10 μg/L or a biopsy Gleason score of at least 7 points 
received bilateral lymph adenectomy. Postoperatively, 
PSA concentrations were measured every 3 months for 
the ﬁ rst year, every 6 months for 2 years, and then yearly. 
Adjuvant radiotherapy was discussed and oﬀ ered to 
patients with positive surgical margins or extracapsular 
disease. The centre urologist held a review appointment 
with participants if their postoperative PSA con-
centrations reached 0·2 μg/L or higher to discuss 
adjuvant radiotherapy.
A linked translational study obtained biological 
specimens and epidemiological data.9
Outcomes
Outcome measures were selected for relevance to patients 
and health-care providers. The primary outcome was 
deﬁ ned as deﬁ nite or probable prostate cancer mortality, 
including intervention-related deaths, at a median of 
10 years’ follow-up. Participants were linked to the NHS 
national registry to obtain vital status information, with 
the information updated quarterly. The process used to 
assess cause of death was adapted from the PLCO 
algorithm5 and ERSPC process3 and then combined to 
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assess deaths in both the CAP and ProtecT studies. The 
medical records of deceased participants were summarised 
by trained CAP researchers, anonymised, and reviewed by 
an indepen dent endpoint committee who were masked to 
ProtecT and CAP trial10 assignments (ﬁ gure 1).
Secondary outcomes include overall mortality (taken 
from death certiﬁ cates), and incidence of metastases, 
local disease progression, treatment complications, and 
resource use for the cost-eﬀ ectiveness analysis (recorded 
on case report forms by specialist nurses every year from 
medical records and participant information). Patient-
reported quality-of-life outcomes include the Expanded 
Prostate Index Composite (added in 2005 for 
rectal complications), International Consultation on 
Incontinence Questionnaire, International Continence 
Society (ICS) urinary ICSmaleSF and sexual function 
ICSsex measures, European Organisation for the 
Research and Treatment of Cancer QLQ-C30 (added in 
2005 for cancer-speciﬁ c eﬀ ects), Hospital Anxiety and 
Depression Scale for psychosocial eﬀ ects, and the Short 
Form-12 and EuroQol-5D generic health status 
measures.18–25 These validated questionnaires were 
completed at recruitment, at ﬁ rst biopsy, 6 months after 
randomisation, and yearly thereafter for at least 10 years. 
Qualitative interviews investigated participants’ experi-
ences of treatments and outcomes. A full list of all 
prespeciﬁ ed outcomes can be found in our study protocol.
Statistical analysis
Before the start of the trial, a sample-size target of 
1434 randomly assigned men (478 in each group) was 
identiﬁ ed as suﬃ  cient to estimate the absolute diﬀ erence 
in mortality probability between two treatment groups 
with a 95% CI of ±0·045, on the basis of an assumed 
mortality rate of 15%, consistent with prostate cancer-
speciﬁ c mortality in men aged 55–69 years with clinically 
detected disease managed conservatively at that time and 
a diﬀ erence that would be deemed clinically signiﬁ cant 
by the NHS. The pilot study recruitment data were used 
to calculate the number of sites and duration of 
recruitment needed to meet the sample size target. 
However, more recent data10 suggested that disease-
speciﬁ c mortality with non-radical treatment was likely to 
be closer to 10% at 10 years, because of improvements in 
disease management. As a result, the DMC advised in 
2008 that recruitment should continue to the planned 
end date, with 1590 men (530 per group) expected to be 
randomly allocated by that point. This sample size would 
enable a 46% reduction in prostate cancer mortality to be 
detected with 80% power at a 5% signiﬁ cance level for a 
pairwise comparison of a radical treatment with active 
monitoring. This calculation assumes a 10% prostate 
cancer-speciﬁ c mortality at 10 years with active 
monitoring, and hence a 5·4% risk with radical 
treatment—an absolute diﬀ erence very similar to the 
margin of error speciﬁ ed in the ﬁ rst calculation. These 
sample size targets are based on diﬀ erences in and ratios 
of risk rather than the hazard ratios planned for the 
primary analysis, because the resulting calculations are 
simpler and more ﬂ exible. When a high survival rate is 
expected, calculations based on risk ratios will be a close 
approximation to those based on hazard ratios. The 
primary analyses will be done on an intention-to-treat 
basis comparing treatment groups as allocated. When a 
median of 10 years of follow-up has accumulated 
(November, 2015), the primary outcome measure of 
prostate cancer mortality will be compared between 
treatment groups using a survival analysis (Cox 
proportional hazards regression model) adjusted for 
stratiﬁ cation and minimisation variables. The estimated 
relative treatment eﬀ ect for each pairwise comparison of 
treatments will be captured as a hazard ratio, and 
presented with a 95% CI. Hazard ratios are interpreted in 
the same way as rate ratios; the advantage of hazard 
ratios and Cox’s proportional hazards model for this 
study is the accommodation of variation in the underlying 
rate of prostate cancer mortality during follow-up. 
Pairwise signiﬁ cance tests will only be done if a test of an 
equal 10-year disease-speciﬁ c mortality risk across all 
three groups yields a p value of less than 0·05.26 This 
approach will be used for event-based secondary 
outcomes—ie, grouped analyses of deﬁ nite, probable, or 
possible prostate cancer, all-cause mortality, and 
metastatic disease.
Pairwise comparisons of symptom burden will use 
multilevel models for repeated measures to estimate the 
average treatment eﬀ ect over the median 10-year follow-
up. Further analyses will investigate the relative burden 
between treatment groups over time. Prespeciﬁ ed 
subgroup analyses will investigate whether treatment 
eﬀ ectiveness in the reduction of prostate cancer-speciﬁ c 
mortality is modiﬁ ed by baseline clinical stage, Gleason 
grade, age, or PSA concentration using stratiﬁ ed 
analyses for descriptive statistics and by formally 
including interaction terms in the relevant regression 
models. Secondary analyses will estimate the eﬃ  cacy of 
radical treatment versus active monitoring in the 
reduction of prostate cancer mortality in individuals who 
complied with their allocated treatment, by using a 
method to derive an unbiased estimate in parallel with 
the per-protocol analysis originally speciﬁ ed in the trial 
protocol.27,28 An analysis of primary and secondary 
outcome measures by trial group is reported yearly to 
the DMC. The DMC recommends changes to the trial 
steering committee if clear evidence (of the order of 
p<0·001) of a positive or negative balance of risks and 
beneﬁ ts emerges for one intervention in comparison 
with the others.
Data from the recruitment, diagnostic, and random-
isation phases are presented, and categorisation of 
continuous variables is either based on clinical thresholds 
(eg, for PSA) or the aim of equal group sizes (other 
measures). Resident area-based material and social 
deprivation scores (the proportion of people living in an 
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area of material deprivation) were derived using Lower 
Super Output Areas, each equating to around 
1500 residents for England, Scotland, and Wales separately.
Analyses were done with STATA version 10. This study 
is registered as an International Standard Randomized 
Controlled Trial, number ISRCTN20141297, and with 
ClinicalTrials.gov, number NCT02044172.
Role of the funding source
The funder had no role in the design or conduct of the 
study; in collection, management, analysis, or inter-
pretation of the data; or preparation, review, or approval 
of the report. JAL, FCH, JLD, and DEN had full access to 
all the data for this analysis (full outcome data will 
become accessible to them from Nov 15, 2015) and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Between Oct 1, 2001, and Jan 20, 2009, 228 966 men were 
invited to participate in the ProtecT study, of whom 
122 502 (54%) responded, although 5954 (5%) of 
respondents declined to participate and 16 104 (13%) did 
not attend the appointment with the specialist nurse 
(ﬁ gure 2). Of the 100 444 (44%) men who did attend, 
82 429 (82%) were eligible and agreed to enrol. Of the 
men who attended their appointment, 10 350 (10%) did 
not enrol or return their second consent form and 
7665 (8%) were deemed ineligible.
73 538 (89%) of the 82 429 recruited participants had a 
PSA concentration that was below the biopsy cutoﬀ  point. 
Only 279 (<1%) had PSA concentrations of 20 μg/L or 
higher and were referred for further assessment outside 
the trial. Of the men tested, 8566 (10%) were referred for 
biopsies, with high levels of uptake (7414 [87%]). The 
remainder (1152 [13%]) did not receive biopsies because 
they either opted to receive monitoring in primary care, 
or had comorbidities that precluded biopsies. Further 
Figure 2: Flow diagram of the diagnostic phase of the main ProtecT trial
Results are from one round of PSA testing. ASAP=atypical small acinar 
proliferation. PIN=prostatic intraepithelial neoplasia. PSA=prostate-speciﬁ c 
antigen.
228 966 men aged 50–69 years were invited to participate
106 464 did not respond
122 502 responded
22 058 did not attend
   5954 declined to participate
  16 104 did not attend
            appointment
100 444 attended appointment
18 015 not recruited
 7665 ineligible
 10 350 declined to participate
82 429 were recruited
73 863 ineligible PSA results
 73 538 <3·0 μg/L
  279 ≥20·0 μg/L
  46 results not given
8566 had an eligible PSA result
1152 did not receive biopsy
7414 received prostate biopsies
 5468 single biopsy
 1946 more than one biopsies
4518 biopsy negative or other
 3504 biopsy negative or mild 
  atypia
 756 high grade PIN
 255 ASAP
 3 inadequate specimen
2896 had a positive biopsy result for prostate cancer
479 ineligible
 270 advanced disease
 209 localised but excluded
   
2417 eligible for randomisation (localised prostate cancer)
No prostate cancer 
diagnosed (n=79 208)*
Prostate cancer 
diagnosed (n=2896)
p value
Age (years) 58 (49–72)† 62 (49–70)† <0·0001 
Ethnic origin 0·10‡
White 77 486 (98%) 2839 (98%)
African-Caribbean 215 (<1%) 11 (<1%)
Other 1507 (2%) 46 (2%)
Married or living with partner 66 178 (84%) 2420 (84%) 0·88
Living in area of deprivation§ 10 706 (14%) 407 (14%) 0·34
Family history of prostate cancer 4082 (5%) 220 (8%) <0·0001 
PSA (μg/L) <0·0001 
Median (range) 0·9 (<0·1–19·9) 4·8 (3·0–19·9)
Mean (SD) 1·3 (1·3) 6·0 (3·3)
Data are median (range) or number (%), unless otherwise indicated. Results are from one round of PSA testing. 
PSA=prostate-speciﬁ c antigen. *Ineligible participants were excluded (for 46 patients the PSA result was not available 
and 279 had a PSA concentration of ≥20 μg/L). †129 men were 49 years of age when the primary care list was 
generated, 120 of whom were 50 years old by recruitment; 25 men were 70 years or older at generation of the primary 
care list, of whom four were 71 years of age and one was 72 years of age; at the time of recruitment, all men who were 
enrolled ﬁ tted the stated inclusion criteria as per protocol. ‡p value is a result of the comparison between white ethnic 
origin and all other ethic origins. §Based on resident area-based material and social deprivation scores—eg, percentage 
of social housing.
Table 1: Demographic and clinical characteristics according to diagnosis of prostate cancer in patients 
recruited into the main ProtecT trial
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biopsies were oﬀ ered to the 2357 (32%) men without a 
deﬁ nitive diagnosis; 1563 (66%) of those oﬀ ered 
underwent the repeat procedure, with a further 322 (14%) 
receiving a repeat biopsy after advice from a urologist.
2896 men were diagnosed with prostate cancer (4% of 
those recruited; 39% of those who had a biopsy). 
2478 (86%) men with prostate cancer were diagnosed at 
initial biopsy with 418 (14%) diagnosed after repeat 
biopsies. 2417 (83%) of the men diagnosed with prostate 
cancer had clinically localised prostate cancer and were 
eligible for randomisation. Additionally, of men with a 
positive biopsy result, 270 (9%) were ineligible for 
randomisation because they had locally advanced, 
advanced, or metastatic disease, and 209 (7%) were 
excluded because of comorbidity.
Predominantly, recruited ProtecT participants were 
white and married or living with a partner, and 4082 (5%) 
reported a family history of prostate cancer (table 1). 
Median age was 58 years (range 50–69) in the total 
cohort, with slightly more men younger than 60 years 
recruited than older men (table 2), and 11 011 (13%) men 
had received a previous PSA test. A positive relation was 
noted between a raised PSA concentration, increased 
age, and receipt of biopsy. The proportions of patients 
who underwent biopsy were similar between all age 
groups (table 2). The relation between higher PSA 
concentrations and prostate cancer diagnosis was 
unchanged by adjustment for age, whereas the relation 
between the proportion of recruited patients diagnosed 
with prostate cancer and increased age was attenuated by 
adjustment for PSA concentration (unadjusted odds 
ratio [OR] data not shown; table 2). Ethnic origin, married 
or partnership status, and extent of material deprivation 
did not diﬀ er between participants diagnosed with cancer 
and those without cancer (table 1).
2417 men recruited to the main ProtecT trial were 
eligible, as were 247 from the feasibility pilot phase.8 
1643 (62%) of these eligible patients agreed to 
randomisation (ﬁ gure 3). The median age of all randomly 
assigned participants was 62 years (range 50–69) with a 
median PSA of 4·6 μg/L (range 3·0–19·9). Most 
participants with prostate cancer had T1c disease and a 
Gleason score of 6 points (table 3). The distributions of 
age, PSA results, Gleason scores, and disease stage were 
well balanced across randomised groups (table 3). The 
median follow-up is currently 8·6 years (IQR 7·1–10·4) 
and we have obtained vital status (primary outcome) info 
for 99% of patients, and secondary outcomes have been 
measured in 93%.
Of the 997 men who declined to be randomly assigned 
and expressed a preference for a particular treatment, 
529 (53%) opted for active monitoring, 273 (27%) for 
radical prostatectomy, 133 (13%) for radiotherapy, 50 (5%) 
for brachytherapy, and 12 (1%) selected other treatments. 
Recruited 
(n=82 429)
Eligible for biopsy (n=8566) Received biopsy (n=7414) Diagnosed with prostate cancer 
(n=2896)
Proportion of tested patients with 
prostate cancer
n (%) Unadjusted OR 
(95% CI)
n (%) Adjusted OR† 
(95% CI)
n (%) Adjusted OR† 
(95% CI)
Diagnosed/PSA 
tested (%)
Adjusted OR* (95% CI)
Age (years)†
50–54 23 381 (28%) 1003 (4%)‡ NA 892 (89%)‡ NA 321 (36%)‡ NA 1·4%‡ NA
55–59 24 870 (30%) 2106 (8%) 2·06 (1·91–2·23) 1859 (88%) 0·91 (0·72–1·16) 693 (37%) 1·03 (0·87–1·22) 2·8% 1·01 (0·85–1·19)
60–64 19 859 (24%) 2766 (14%) 3·61 (3·35–3·89) 2397 (87%) 0·76 (0·61–0·96) 966 (40%) 1·10 (0·94–1·30) 4·9% 1·04 (0·89–1·22)
65–69 14 189 (17%) 2689 (19%) 5·22 (4·84–5·63) 2264 (84%) 0·62 (0·49–0·78) 915 (40%) 1·09 (0·92–1·28) 6·4% 0·98 (0·84–1·15)
PSA (μg/L)§
<3·0¶ 73 538 (89%) 0 NA NA NA NA NA NA NA
3–3·9 3689 (4%) 3689 (100%) NA 3090 (84%)‡ NA 951 (31%)§ NA 25·8%‡ NA
4·0–9·9 4290 (5%) 4290 (100%) NA 3785 (88%) 1·49 (1·31–1·69) 1568 (41%) 1·58 (1·43–1·75) 36·6% 1·66 (1·50–1·83)
10·0–19·9 587 (<1%) 587 (100%) NA 539 (92%) 2·32 (1·70–3·17) 377 (70%) 5·15 (4·17–6·35) 64·2% 5·16 (4·25–6·26)
Percentages are calculated using previous category as a denominator. OR=odds ratio. PSA=prostate-speciﬁ c antigen. NA=not applicable. *ORs for age were adjusted for PSA concentration, and ORs for PSA 
were adjusted for age. †Date of birth could not be obtained or age was out of eligible range for 130 recruited participants; age was out of eligible range for two participants invited for biopsy; two participants 
who received biopsy; and one participant who was diagnosed with prostate cancer. ‡Reference category. §PSA results were not available for 46 recruited participants, and 279 recruited participants had a PSA 
result of 20 μg/L or higher and hence were excluded. ¶Ineligible for biopsy.   
Table 2: PSA distribution, biopsy, and prostate cancer diagnosis by age and PSA concentration in the main ProtecT trial
Figure 3: Flow diagram of the randomisation phase of th e ProtecT trial
1643 participants were randomly assigned
 1497 from main trial
 146 from pilot study
2664 participants were eligible
 2417 recruited in main trial
 247 recruited in pilot study
1021 were not randomly assigned
 997 selected treatment 
 24 were randomly assigned to two groups
545 allocated to active monitoring 545 allocated to radiotherapy 553 allocated to surgery
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These participants had similar clinical and socio-
demographic characteristics to those who were randomly 
assigned (table 4), except that they were less likely to 
reside in an area of material deprivation (OR of increased 
deprivation in randomised versus non-randomised 
participants of 0·74 [95% CI 0·58–0·94]).
Discussion
The ProtecT trial recruited and tested more than 
82 000 community-based men aged 50–69 years. More 
than 8000 men had a PSA concentration of 3·0 μg/L or 
more, and of those, 87% received a biopsy, resulting in 
nearly 3000 men diagnosed with prostate cancer (4% of 
those recruited). Including eligible men recruited in the 
pilot study, 1643 (62%) of 2664 participants were 
randomly assigned to active monitoring, radical 
prostatectomy, or radiotherapy. In this initial report, 
median 8-year follow-up is more than 93% for all 
endpoints (99% for the primary outcome).
The ProtecT trial was designed to address key issues in 
the management of clinically localised prostate cancer, 
speciﬁ cally the comparative eﬀ ectiveness and cost-
eﬀ ectiveness of the three conventional treatment 
modalities, including the trade-oﬀ  between early 
diagnosis with PSA testing and the risks of over-detection 
and over-treatment. Trial design features that will 
enhance the robustness of the ﬁ ndings include 
standardised diagnostic, treatment, and follow-up proto-
cols; internal and external quality assurance processes; 
allocation concealment; high compliance with follow-up; 
extensive secondary outcomes; and an independent, 
masked primary endpoint committee. Randomisation 
was successful and baseline characteristics were evenly 
distributed across treatment groups. However, the study 
does have some limitations. The recruitment process 
was based on PSA testing, which is known to over-detect 
prostate cancer, and has the potential to be superseded by 
newer diagnostic modalities such as pre-biopsy imaging. 
Additionally, the long natural history of the disease 
means that the study will have taken more than 15 years 
to report, from ﬁ rst patient participation in 1999 to the 
planned analysis of primary outcome after a median 
10-year follow-up in November, 2015. Furthermore, 
during the past decade radical surgery has evolved with 
the introduction of robot-assisted and laparoscopic 
techniques, but few of these new approaches were 
undertaken in this trial. Other treatments have also 
changed: brachytherapy, dose escalation, and intensity-
modulated radiotherapy are not being assessed in 
ProtecT, and active surveillance cohorts now tend to 
focus on men with a Gleason score of 6 points and use 
scheduled prostate biopsies—eg, PRIAS (Prostate Cancer 
Research International Active Surveillance).29 Another 
limitation is that the lack of ethnic diversity in the study 
population might limit the applicability of the ProtecT 
ﬁ ndings to non-white populations. Also, men younger 
than 50 years or older than 69 years were not eligible, nor 
Active monitoring 
(n=545)
Radiotherapy 
(n=545)
Radical prostatectomy 
(n=553)
Age at invitation (years)
49–54 58 (11%) 62 (11%) 69 (12%)
55–59 140 (26%) 141 (26%) 137 (25%)
60–64 184 (34%) 176 (32%) 172 (31%)
65–69 163 (30%) 166 (30%) 175 (32%)
Median age (range) 62 (50–69) 62 (49–69)* 62 (50–69)
PSA (μg/L)
3·0–5·9 373 (68%) 373 (68%) 371 (67%)
6·0–9·9 116 (21%) 121 (22%) 123 (22%)
≥10·0 56 (10%) 51 (9%) 59 (11%)
Median PSA (range; μg/L) 4·6 (3·0–20·9)† 4·6 (3·0–18·8) 4·7 (3·0–18·4)
Gleason score
6 421 (77%) 423 (78%) 422 (76%)
7 111 (20%) 108 (20%) 120 (22%)
8–10 13 (2%) 14 (3%) 10 (2%)
Missing 0 0 1 (<1%)
Clinical stage
T1c 410 (75%) 429 (79%) 410 (74%)
T2 135 (25%) 116 (21%) 143 (26%)
Data are number (%) or median (range). *One person was aged 49 years when the primary care list was generated, but ﬁ tted 
the stated inclusion criteria as per protocol. †One patient from the feasibility study had a serum PSA concentration of 
20·9 μg/L at the specialist nurse visit; the concentration fell to 17·6 μg/L on repeat measurement and he became eligible for 
recruitment.
Table 3: Participant and clinical characteristics at randomisation in the ProtecT trial
Randomised (n=1643) Non-randomised (n=997) p value
Age (years)* 62 (49–69)† 62 (50–69) 0·60
Ethnic origin 0·31‡
White 1606 (98%) 984 (99%)
African-Caribbean 10 (<1%) 2 (<1%)
Other 37 (2%) 11 (1%)
Married or living with partner 1375 (84%) 841 (84%) 0·72
Living in area of deprivation§ 239 (15%) 111 (11%) 0·015
Family history of prostate cancer 119 (7%) 83 (8%) 0·28
PSA (μg/L) 5·8 (3·0) 5·8 (3·1) 0·67
Gleason score 0·42
6 1266 (77%) 755 (76%)
7 339 (21%) 218 (22%)
8–10 37 (2%) 24 (2%)
Missing 1 (<1%) 0
Clinical stage 0·96
T1c 1249 (76%) 758 (76%)
T2 394 (24%) 239 (24%)
Data are median (range) or number (%). *24 patients are classiﬁ ed as non-randomised because they were part of 
the early study with randomisation only between radical treatments (not active monitoring). †One person was aged 
49 years when the primary care list was generated, but ﬁ tted the stated inclusion criteria as per protocol. ‡p value is a 
result of the comparison between white ethnic origin and all other ethic origins. §Based on resident area-based 
material and social deprivation scores using several indicators of income and living conditions—eg, percentage 
of social housing.
Table 4: Demographic and clinical characteristics at randomisation according to randomisation status in 
the ProtecT trial
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were men with a PSA concentration of 20 μg/L or higher 
because they were likely to harbour non-localised cancer 
and an increased risk of lymph node metastasis, as 
shown by Joniau and colleagues.30 Although we 
acknowledge that recent advances in imaging techniques 
would have improved staging in these patients, only 279 
(0·3%) of 82 429 participants in our tested cohort had a 
PSA concentration of 20 μg/L or higher.
Additionally, the recruited population could be generally 
healthier than the overall population, as often occurs in 
screening trials, but this does not aﬀ ect the compara tive 
eﬀ ectiveness analyses of treat ments.3,5 Furthermore, UK 
statistics in 2008 suggested that prostate cancer mortality 
in the active monitoring group would be around 10% 
after 10 years—lower than expected at the trial outset. 
Therefore  the mortality risk diﬀ erence of 4·6%, upon 
which the original sample size was based, roughly 
corresponds to a hazard ratio of 0·54 in the revised 
calculation—a substantial beneﬁ t of radical compared 
with conservative management. Should results from this 
trial support early active intervention, evidence will be 
needed that beneﬁ ts are suﬃ  ciently large to outweigh the 
well recognised complications of radical treatments. 
The primary analysis will be highly informative for 
clinicians, patients, and decision makers because the 
trial has been designed to consider mortality, resource 
use, and quality-of-life outcomes. And, as with the other 
treatment trials, the ﬁ ndings will continue to be of 
interest as the data mature over time.
The study’s limitations need to be balanced against a 
number of strengths that ensure that the ProtecT trial 
will be of pivotal importance in establishing the 
comparative eﬀ ectiveness of the three most frequently 
used treatment options in PSA-detected clinically 
localised prostate cancer. It is the largest ongoing 
randomised controlled trial of prostate cancer treatments 
worldwide, with standardised protocols for diagnosis, 
treatment, and follow-up and enabling an assessment of 
screening through the linked CAP trial. The core age 
group of the ProtecT trial is similar to that of other 
randomised control trials. High levels of generalisability 
are assured by embedding ProtecT within the CAP 
randomised control trial of population-based PSA testing 
involving about 1·5% of all UK men aged 50–69 years 
recruited from randomly selected primary care centres. 
Participants with intermediate and some high-risk 
disease features were included and will help to establish 
whether active monitoring protocols can oﬀ er an 
alternative to immediate radical intervention in these 
patients. The planned subgroup analyses of treatment 
ERSPC (Europe)3 PLCO (USA)5 ProtecT (UK) PIVOT (USA)6 SPCG-4 (Sweden)7
Interventions Screening vs control Screening vs control AM vs RP vs RT RP vs WW RP vs WW
Recruitment period 1993–99 1993–2001 1999–2009 1994–2002 1989–99
PSA biopsy threshold (μg/L) 3·0/4·0 4·0 3·0 NA NA
Number of biopsy cores 6 Variable 10 NA NA
Men invited 68 896 NK 228 966 NA NA
Men attended NK 38 350 100 444 NA NA
PSA tested (% of attendees)* 56 064 (29–91%)† 34 244 (89%) 82 559 (82%)‡ NA NA
Raised PSA results 10% 8% 10% NA NA
Biopsy uptake 84% 32% 87% NA NA
Diagnosed with prostate cancer 2·7% 1·6% 3·5% NA NA
Randomly assigned to treatment NA NA 1643 (62%) 731 (15%) 695 (NK)
Age range, years (mean age) 55–69 (60–63§) 55–75 (60) 50–69 (61) <75¶ (67) <75¶ (65)
White ethnic origin NK 86% 99% 62% NK
Mean PSA, μg/L NK NK 5·8 10·1 13·0
Clinical stage*
T1 42% 0·5% 76% 50% 11%
T2 28% 96% 24% 40% 75%
T3 11% 4% 0|| 0 0
Not recorded 17% 0·4% 0 10% 14%
Gleason score*
2–6 (ERSPC 2–7)** 91% 63% 77% 74% 60%
7–10 (ERSPC 8–10)** 6% 31% 23% 19% 28%
Not recorded 3% 2% 0 7% 12%
AM=active monitoring. RP=radical prostatectomy. RT=radiotherapy. WW=watchful waiting. NA=not applicable. NK=not known. *Screening group. †Uptake varied across 
countries and methods of identifying men. ‡82% of attendees; 36% of all those invited. §Varied by country (ERSPC) or estimated from age distribution in quartiles. ¶Lower age 
limit unknown. ||9% of patients had T3/advanced disease, but were ineligible for randomisation so are not shown here. **ERSPC Gleason grades 2–4 (15%) and 5–7 (76%) have 
been combined; 8–10 (6%).
Table 5: Design, and participant and clinical characteristics, of the principal screening and treatment trials in clinically localised prostate cancer
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eﬀ ectiveness by stage and grade will investigate this 
aspect and assist comparison with SPCG-4 and PIVOT 
treatment trial patients. Furthermore, the assessment of 
a radiotherapy and neoadjuvant regimen will be relevant 
for patients with higher risk disease because good 
evidence already exists for endocrine therapy combined 
with radiotherapy for advanced disease.31
ProtecT detected more prostate cancer in the ﬁ rst 
round of testing than did the ERSPC and PLCO trials, 
probably because of ProtecT’s lower PSA threshold 
combined with the minimum ten-core biopsy protocol in 
a population previously unexposed to routine PSA 
testing. The clinical characteristics of the participants’ 
cancers in the ProtecT trial are similar to those of other 
unscreened populations.32 Cancer was generally detected 
at a lower stage and grade in ProtecT participants than in 
a UK cohort of patients with clinically detected prostate 
cancer in the early 2000s.33 However, this reduction in 
stage and grade would have been mitigated by the 
upward grade migration reported in Gleason scoring in 
NHS practice between 2000 and 2010.34 Nevertheless, the 
mean proportion of UK men whose PSA concentration 
has been tested remains low by international standards 
at 6% (range 2–9) in primary care centres in the mid-
2000s. Compared with the PIVOT6 and SPCG-47 
treatment trials, ProtecT participants had the lowest PSA 
concentration, age, and included fewer higher stage 
cancers at the point of randomisation (table 5). 
Randomisation of eligible participants was higher in 
ProtecT (62%) than in PIVOT (15%), and other similar 
trials did not complete recruitment (eg, START, SPIRIT). 
The acceptability of randomisation in the ProtecT trial 
was enhanced by integrated qualitative research.35 Most 
notably, ProtecT participants received active monitoring, 
not watchful waiting as in PIVOT6 and SPCG-4.7 Current 
active surveillance protocols have more restrictive entry 
criteria and rely more on scheduled re-biopsy than in 
ProtecT, but ProtecT trial results will provide, to our 
knowledge, the ﬁ rst randomised evidence for a 
monitoring strategy that includes the option of radical 
treatment (panel).
In 2016, the ProtecT trial will provide data for the 
comparative eﬀ ectiveness and cost-eﬀ ectiveness of active 
monitoring, radical prostatectomy, and radiotherapy in 
men diagnosed with localised prostate cancer after PSA 
testing with a median 10-year follow-up. These treatments 
are the major conventional options, and will be compared 
within an entirely PSA-tested cohort. The major ﬁ ndings 
will provide key information needed to underpin the 
management of clinically localised prostate cancer, 
including the crucial trade-oﬀ  between survival gains and 
potential harm caused by over-detection and unnecessary 
radical treatment in PSA-detected prostate cancer.
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possible because of the heterogeneity of extracted results. The 
systematic review concluded that there was insuﬃ  cient 
evidence to establish the eﬀ ectiveness or cost-eﬀ ectiveness of 
screening or treatments for localised prostate cancer because 
of the shortage of robust randomised evidence at the time.
Interpretation
The ProtecT trial is, to our knowledge, the largest 
contemporary randomised controlled trial investigating the 
eﬀ ectiveness of conventional treatment options in men with 
clinically localised prostate cancer detected after PSA testing. 
The ProtecT trial clearly diﬀ ers from two previously published 
treatment trials6,7 that compared surgery with watchful 
waiting (a passive observational option) in men with clinically 
detected disease (SPCG-4)7 and older Veterans Administration 
men with PSA-detected disease (PIVOT).6 In the ProtecT trial, 
these baseline results show that we successfully recruited men 
aged 50–69 years after community-based PSA testing and a 
high proportion agreed to be randomly assigned between the 
three major conventional contemporary options (surveillance, 
surgery, and radiotherapy), and have achieved high levels of 
follow-up. The data presented provide information about one 
round of testing and diagnosis in a population without 
extensive routine PSA testing. In 2016, the trial will publish its 
outcome data.
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